Dr. Rod Ferguson participates as an advisor, board member, mentor and investor at MotionHall. One of few senior dealmakers who has experienced strategic transactions from all sides of the table, Rod is able to comment on the complexities of transactions and their stakeholders from the perspective of a biotech, pharmaceutical company, venture investor and investment banker. A respected industry name, Rod has led some of the most widely recognized pharmaceutical licensing deals in the world including Genentech's in-licensing of Rituxan and auction of Herceptin.

Rod is the Managing Director of Panorama Capital, a venture capital firm which spun off from J.P. Morgan Partners (JPMP) in July 2006, where he oversees the firm's life sciences investments. He joined JPMP as a Managing Director in their life sciences venture practice in 2001. From 1999 to 2001, Dr. Ferguson was a partner at InterWest Partners, a venture capital firm. Prior to InterWest, he held a variety of management positions over an 11-year career at Genentech, Inc., most recently as Senior Director of Business and Corporate Development responsible for worldwide licensing transactions for both technology and pharmaceutical products. Prior to joining Genentech, Inc. in 1988, Dr. Ferguson was an associate with the law firm McCutchen, Doyle, Brown, & Enersen (currently known as Bingham McCutchen llp).

Rod presently serves on the technology advisory board of The Economist, a variety of advisory boards in the life sciences industry, two non-profit boards and several private biotech company boards.

Dr. Ferguson received a B.S. with honors in Biochemistry from the University of Illinois, a PhD in Biochemistry from the State University of New York at Buffalo, and a J.D. cum laude from Northwestern University.